Breaking News

Longboard Pharmaceuticals announced topline results from a Phase 1 clinical study evaluating the central nervous system, or CNS, pharmacokinetics, or PK, and pharmacodynamics, or PD, of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers. The primary objectives of this open-label, Phase 1 study are to assess the CNS PK and PD of orally administered LP352 in healthy adult male and female participants. Objectives include the characterization of plasma and CSF PK, the characterization of safety and tolerability of doses with titration and taper, and the assessment of the PK-PD relationships between plasma and CSF exposure, and PD endpoints of safety and efficacy, including quantitative electroencephalogram endpoints. Data being shared relate to two doses of LP352 three times daily that were tested over a 16-day period in addition to a screening and follow-up period. Additional cohorts of the study are ongoing. Plasma samples were obtained on Day 1 through Day 11, measuring maximum concentration, time of peak plasma concentration and area under the curve. Serial CSF samples were taken on Day 11 at multiple timepoints. At steady state, LP352 12 mg TID mean concentrations exceeded the Ki value for 5-HT2C activity throughout the dosing interval. The vast majority of participants in Cohort 2 achieved plasma and CSF levels above the relevant Ki throughout the dosing period at steady state. LP352 exhibited a strong correlation between plasma and CSF PK concentration, which increased in a dose-dependent and consistent manner. Serial EEGs were taken at Days -1, 1, 3 & 10, and Day 16. LP352 demonstrated early qEEG changes within the first few doses. LP352 also demonstrated sustained, dose-dependent effects on qEEG activity after continuous dosing, thus indicating receptor engagement. LP352 engaged neurotransmitter systems and altered the EEG spectrum. Favorable safety and tolerability across both cohorts were observed, with AEs generally consistent with previous clinical studies of LP352.